Milliman Acquires Torch Insight, Expanding Industry’s Leading Portfolio of SaaS Health Market Intelligence Solutions
Milliman, Inc. announced the acquisition of Torch Insight from Leavitt Partners, LLC. This acquisition will combine Torch Insight’s powerful market-centered data and analytics with MedInsight, Milliman’s flagship healthcare analytics ecosystem.
Torch Insight brings Milliman decades of healthcare policy expertise and healthcare analytic experience backed by Leavitt Partners – recognized experts in the health sector. The team has integrated and linked thousands of data elements from dozens of public and proprietary data sources. The platform is the culmination of thousands of hours spent cleaning and validating data and splicing together siloed data sets to enable powerful market-centered analysis and data visualization, and integration with business intelligence platforms.
Recommended AI News: SHL Redefines How Organizations Shape Their Talent Management Strategies
MedInsight founder and Milliman Principal Kent Sacia believes the acquisition of Torch Insight by Milliman represents a significant advancement in healthcare analytics. “Torch Insight and MedInsight are incredibly complementary to each other. MedInsight enables clients to apply robust, value-added analytic techniques to their own data. Torch Insight expands the scope of these analytics by layering in comprehensive data about the surrounding environment and delivery system. Together, MedInsight and Torch Insight provide a 360-degree view of client results in the context of their local healthcare market dynamics, competition, and partner relationships.”
Leavitt Partners Founder and Chairman, and former Secretary of the U.S. Department of Health and Human Services, Mike Leavitt, remarked, “Combining Torch Insight’s comprehensive data on the unique attributes of ACOs, bundled payments, and healthcare stakeholder relationships with MedInsight’s analytic suite, creates the most thorough market intelligence asset available.”
Recommended AI News: Using AI and Machine Learning for Repurposing Drugs as Potential COVID-19 Therapies